Sep 26, 2023 / 12:10PM GMT
Ross Osborn - Cantor Fitzgerald LP - Analyst
Good morning, everyone, and thank you for joining. My name is Ross Osborn. I'm the medtech, life science tools, and diagnostics analyst at Cantor. And today, we are joined by Absci Corporation with Alex Kahn, VP of Finance and Head of Investor Relations.
Questions and Answers:
Ross Osborn - Cantor Fitzgerald LP - AnalystSo Alex, would you just provide a brief overview of your Company and yourself for those less familiar with the story?
Alex Khan - Absci Corporation - VP, Finance & IR
Greg. Thank you, Ross, and thank you to Cantor for the opportunity to be here today. And we appreciate it.
So at Absci, we're merging AI with scalable wet lab technologies with a mission to create better biologics for patients faster. And the company that we are today is fundamentally different than where we were at our founding. And even for those who knew us around the time of the IPO, we really evolved a lot since then.
So at our founding, our Founder and CEO,